Thinly traded nano cap Tiziana Life Sciences plc (NASDAQ:TLSA) rockets 91% premarket on average volume in reaction to its announcement that
it has developed an investigational new technology that enables the
direct delivery of IL-6-inhibiting monoclonal antibodies into the lungs
via a handheld inhaler or nebulizer.
The company says the technology advances its IL-6
candidate TZLS-501 for the potential treatment of COVID-19, adding that
it could be useful with other antibodies and drugs. A provisional patent
application has been filed.
It acquired the candidate from Swiss biotech Novimmune in 2017.
IL-6 is a proinflammatory cytokine (protein) that
is believed to play a key role in the development of severe lung damage
in severely ill COVID-19 patients with acute respiratory distress
syndrome.
https://seekingalpha.com/news/3559578-tiziana-life-sciences-up-91-on-inhalable-treatment-of-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.